Welcome! Defeating Merkel cell carcinoma begins here.
The critical first step is to find a Merkel cell carcinoma specialist.
It is critical that each case be reviewed by a multidisciplinary team, including surgical oncologists, radiation oncologists, medical oncologists, and dermatologists with significant experience in managing MCC, in order to develop a plan for the patient.
To find healthcare professionals experienced with Merkel cell carcinoma, start with our list of verified specialists.Find a Specialist
Make sure your primary care team is knowledgeable and takes action.
Merkel cell carcinoma is rare, and it's common for many medical professionals to be unsure of where to start. When a diagnosis occurs, it is imperative that your medical team is knowledgeable and able to carry out an MCC specialist's plan.
Our clinical team recommends that all healthcare providers follow the NCCN guidelines for MCC to bring them up to speed on MCC and how to care for MCC patients.Get the Guide
Consider joining a patient-based group
A diagnosis of Merkel cell carcinoma is a life-changing experience. Support from others—in the form of advice, recommendations for local healthcare providers, or sharing personal victories—can help ease the burden many MCC patients and their families feel.
We encourage you to make connections; it’s been proven to help.Get Support
The latest advancements in treatment
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
MCC has a high chance (about 60%) of responding to immune therapy with PD-1 blocking agents. Remarkably, the chance that virus-negative MCC tumors will respond to immune therapy is the same as for virus-positive tumors, although the targets the immune system ‘sees’ are very different in nature.
A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma
More than half of patients with advanced MCC will not respond persistently to one of the FDA-approved immune therapies (pembrolizumab or avelumab). Addressing this need is the most pressing issue in our field. This study by Dr. Shalhout and colleagues, carried out in Boston, found that none of 13 pa...
The basis for the activity in Merkel cell carcinoma of an oral ‘MDM2 inhibitor’, milademetan (Rain Therapeutics), is nicely explained in this study. For this therapy to work, the p53 protein (the 'guardian of the genome') must not have been directly mutated in the MCC tumor cells, meaning p53 wo...